Organization | Yisheng Biopharma

Yisheng Biopharma Report issue

For profit Phase 1 Phase 3

Founded: Beijing China (2002)

Status: Defunct (2020)

Organization Overview

First Clinical Trial

2015

NCT02657161

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2024

Timeline

NOW

Now

Alternative names

Yisheng Biopharma CO., Ltd. | Yisheng Biopharma (Singapore) Pte. Ltd.

Active Ingredients

Drugs in Phase 3 Trials (3)

inactivated rabies vaccine (Imovax) (4 trials)

pika covid-19 vaccine (cho cell, s-protein) (2 trials)

pika rabies vaccine (3 trials)

Drugs in Phase 1 Trials (3)

polycytidylic acid (1 trial)

polyinosinic acid (1 trial)

ys-hbv-002 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Rabies (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 7
# of Trial APIs: 6